Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care

MOUNTAIN VIEW, Calif.--(Business Wire)--
Applied Protein Sciences, a biotechnology start-up focused on preventing
mucositis, announced today that it has entered into a strategic alliance with
Biomodels. This alliance allows speedier product development and helps APS
expand its pipeline to develop proprietary drugs for mucositis, proctitis and
IBD. APS expects to launch its clinical program later this year.

"We are very excited about partnering with Biomodels," said Aman Johar, CEO of
APS."This relationship allows us flexibility to customize our pre-clinical
studies, maintain our clinical end-points and effectively utilize capital
resources. A full-scale collaboration extends our research platform and provides
access to leading scientists and researchers. Biomodels` proven models reliably
predict clinical success in an extremely complex field of mucositis. APS
products can be the standard of care for preventing mucositis - saving over $2
billion annually in hospitalization costs."

"Together Biomodels and APS will finalize oral mucositis studies and also
rapidly test a number of mechanistically-related therapeutic areas using
appropriate validated models," said Edward Fey, Managing Partner of Biomodels.
"This alliance represents a new business model for the outsourcing of
pre-clinical services and is designed to fulfill the specific needs of early
stage pharmaceutical companies," Fey adds.

Mucositis remains an unmet medical need and APS products may become the
"standard of care"for solid tumor patients undergoing cancer treatment.
Mucositis affects over 400,000 patients annually. In a recent survey, 66% of
mucositis patients said that physicians need to be educated more about its
treatments. There are currently no approved medications for preventing
mucositis. This collaboration boosts APS efforts to build a technology platform
that can be scaled to encompass all aspects of supportive oncology care.

About Applied Protein Sciences

APS is developing proprietary proteins that help with the growth of the mucosal
tissue, thereby preventing the onset of mucositis. With APS` products, patients
can remain on chemotherapy or radiation for longer, significantly increasing
their survival. In addition to mucositis, APS drug platform includes candidates
for proctitis and IBD - significant unmet medical needs in supportive oncology
care. APS aims to secure orphan drug status and has a broad portfolio of issued
US and worldwide patents rights. APS recently released a mechanism of action for
its drug candidates. APS is privately owned and investors include Innovation
Management Sciences.

www.appliedprotein.com

About Biomodels

Biomodels is a preclinical CRO helping biotechnology companies enter clinical
trials phase of the drug development process. Biomodels specializes in screening
studies to evaluate efficacy and define mechanism of action to expedite the
process. Over the years Biomodels core competencies in oncology and cancer
supportive care include a range of inflammatory and mucosal diseases. The net
effects are preclinical data that are meaningfully translatable to the clinic
and added confidence in the design of clinical studies, all of which conveys
substantial cost savings.

www.biomodels.com

Applied Protein Sciences
Amanjyot S. Johar, 650-969-8300
info@appliedprotein.com
or
Biomodels
Edward G. Fey, 857-228-1100
info@biomodels.com

Copyright Business Wire 2009